Bilateral Vestibular Schwannomas on MRI: A Classic Imaging Presentation of NF2-Related Schwannomatosis


 Edited by ScholarGen MediAI Team

How Contrast-Enhanced MRI Reveals Bilateral Internal Auditory Canal Tumors, Cerebellopontine Angle Extension, and Significant Brainstem Compression in a Young Adult

Executive Answer

Bilateral vestibular schwannomas in a young adult are a highly characteristic imaging manifestation of NF2-related schwannomatosis, historically known as neurofibromatosis type 2 (NF2). Contrast-enhanced brain MRI demonstrates enhancing tumors involving both internal auditory canals (IACs), with extension into the cerebellopontine angles (CPAs) and associated brainstem compression. In this 34-year-old man, the left tumor was associated with severe sensorineural hearing loss, while right-sided hearing remained normal. Recognizing this bilateral imaging pattern is essential because it changes the diagnostic approach from an isolated cranial nerve tumor to a hereditary tumor-predisposition syndrome requiring lifelong multidisciplinary surveillance.

Why This Case Matters

A unilateral vestibular schwannoma is a familiar finding in clinical neuroradiology. Bilateral vestibular schwannomas, however, demand a fundamentally different diagnostic perspective.

When both internal auditory canals contain enhancing tumors, particularly in a relatively young patient, the radiologist should immediately consider NF2-related schwannomatosis.

The importance of this diagnosis extends beyond identifying two benign nerve sheath tumors. It involves recognizing an inherited or mosaic genetic disorder associated with multiple nervous system neoplasms, progressive hearing impairment, cranial neuropathies, and potential complications from posterior fossa mass effect.

This case illustrates three important clinical principles:

  1. Bilateral internal auditory canal tumors should trigger an evaluation for NF2-related schwannomatosis.

  2. Tumor dimensions alone do not determine clinical severity; brainstem compression and cranial nerve function are equally important.

  3. Treatment planning must balance tumor control against preservation of hearing, facial nerve function, and long-term neurological quality of life.

Clinical Case Presentation

A 34-year-old man presented to a neurosurgical clinic with mild imbalance and hearing loss in his left ear.

He had a family history of neurofibromatosis type 2 and had previously been diagnosed with tumors involving both internal auditory canals.

Interestingly, he had not experienced tumor-related symptoms, including hearing impairment or imbalance, before the current presentation. Brain surveillance imaging had been performed since he was 16 years old.

Audiological evaluation demonstrated:

  • Severe sensorineural hearing loss in the left ear.

  • Normal hearing in the right ear.

Contrast-enhanced brain MRI identified bilateral internal auditory canal tumors with extension into the cerebellopontine angles.

The reported tumor dimensions were:

  • Left: 32 × 27 × 31 mm.

  • Right: 31 × 28 × 30 mm.

Both tumors were associated with substantial posterior fossa mass effect and severe brainstem compression.

The combination of bilateral vestibular schwannomas, young age, and a positive family history strongly supported the diagnosis of NF2-related schwannomatosis.

MRI Findings: Bilateral Vestibular Schwannomas


Figure 1. Axial Contrast-Enhanced MRI Demonstrating Bilateral Vestibular Schwannomas

Radiologic Interpretation

The axial contrast-enhanced brain MRI demonstrates two large, avidly enhancing extra-axial masses involving the bilateral cerebellopontine angles and internal auditory canal regions.

The red arrows identify the bilateral tumors.

The lesions demonstrate the characteristic distribution of vestibular schwannomas, with involvement of both internal auditory canals and extension into the adjacent cerebellopontine angle cisterns.

The tumors produce considerable mass effect on the adjacent posterior fossa structures, including significant compression of the brainstem.

The most important diagnostic observation is not simply the presence of two enhancing masses. It is their bilateral anatomical distribution along the vestibular nerve pathways.

Key Imaging Features

  • Bilateral enhancing internal auditory canal tumors.

  • Extension into both cerebellopontine angles.

  • Large tumor dimensions, measuring approximately 3 cm on each side.

  • Significant posterior fossa mass effect.

  • Severe brainstem compression.

The imaging appearance is highly characteristic of bilateral vestibular schwannomas in the setting of NF2-related schwannomatosis.

Why Does a Vestibular Schwannoma Extend Into the Cerebellopontine Angle?

Vestibular schwannomas arise from Schwann cells associated with the vestibular division of cranial nerve VIII.

The tumor typically originates within the internal auditory canal and may progressively extend through the porus acusticus into the cerebellopontine angle cistern.

As the tumor enlarges, its extrameatal component occupies an increasing proportion of the posterior fossa.

This growth pattern explains why large vestibular schwannomas can compress the brainstem and adjacent cerebellar structures.

In advanced cases, the clinical consequences may extend beyond hearing impairment to include disequilibrium, facial nerve dysfunction, trigeminal sensory symptoms, and other neurological manifestations.

Radiologist's Reasoning: Why Bilaterality Changes the Diagnosis

The distinction between unilateral and bilateral vestibular schwannomas is one of the most important diagnostic considerations in this case.

A sporadic vestibular schwannoma generally presents as a unilateral lesion. Bilateral vestibular schwannomas, particularly in a young adult, strongly suggest a hereditary tumor-predisposing syndrome.

The updated international diagnostic terminology is NF2-related schwannomatosis, replacing the historical designation neurofibromatosis type 2.

Under the revised 2022 international consensus criteria, bilateral vestibular schwannomas alone are sufficient to establish the clinical diagnosis of NF2-related schwannomatosis.

Therefore, molecular confirmation is not mandatory when the characteristic bilateral vestibular schwannoma criterion is fulfilled.

Nevertheless, genetic testing remains valuable for identifying the underlying pathogenic variant, evaluating possible mosaicism, and providing appropriate counseling to family members.

NF2-Related Schwannomatosis: The Genetic Basis

NF2-related schwannomatosis is an uncommon genetic tumor-predisposition disorder caused by pathogenic variants affecting the NF2 tumor suppressor gene on chromosome 22q12.2.

The NF2 gene encodes merlin, also known as schwannomin.

Merlin is involved in regulating cell proliferation, cell-to-cell interactions, and signaling pathways responsible for maintaining normal tissue growth.

Loss of normal merlin function disrupts cellular growth regulation and promotes the development of multiple nervous system tumors.

The disorder is inherited in an autosomal dominant manner.

However, not every affected individual inherits the condition from an affected parent. A substantial proportion of cases arise from de novo pathogenic variants.

Somatic mosaicism is another important consideration. In mosaic NF2-related schwannomatosis, the pathogenic variant is present in only a proportion of the body's cells. This may influence disease severity, tumor distribution, and transmission risk.

Associated Tumors and Manifestations

Bilateral vestibular schwannomas are the hallmark manifestation, but the disease is not restricted to the eighth cranial nerves.

Other associated lesions include:

  • Intracranial meningiomas.

  • Spinal schwannomas.

  • Peripheral nerve schwannomas.

  • Spinal ependymomas.

  • Other nervous system tumors.

Ocular manifestations, including juvenile cataracts and retinal abnormalities, may also occur.

Consequently, evaluating a patient with bilateral vestibular schwannomas should not end after the initial brain MRI. The entire neurological and ophthalmological disease spectrum must be considered.

Differential Diagnosis of Bilateral Internal Auditory Canal Masses

Although bilateral vestibular schwannomas are highly characteristic of NF2-related schwannomatosis, a systematic radiological differential remains important.

1. Bilateral Vestibular Schwannomas

These are the leading diagnosis in a young adult with bilateral internal auditory canal and cerebellopontine angle masses.

The typical imaging pattern includes enhancing tumors centered on the internal auditory canals, often with extension into the CPA cisterns.

The combination of bilateral lesions and a compatible family history strongly supports NF2-related schwannomatosis.

2. Bilateral CPA Meningiomas

Meningiomas may occur in patients with NF2-related schwannomatosis and can involve the cerebellopontine angles.

Features favoring meningioma include:

  • Broad-based dural attachment.

  • Dural tail.

  • Adjacent hyperostosis.

  • Less characteristic extension along the internal auditory canal.

The distinction depends on the tumor's anatomical center and its relationship to the dura and cranial nerves.

3. Facial Nerve Schwannoma

Facial nerve schwannomas may mimic vestibular schwannomas when they involve the internal auditory canal or cerebellopontine angle.

Careful evaluation of the facial nerve pathway, including the labyrinthine segment, geniculate ganglion, and facial nerve canal, can help establish the site of origin.

4. Metastatic Disease

Bilateral CPA or internal auditory canal involvement by metastatic disease is uncommon but may be considered in patients with a relevant malignancy history.

Associated leptomeningeal enhancement, additional intracranial lesions, or systemic disease may provide diagnostic clues.

In the present clinical setting, the patient's age, family history, and characteristic bilateral tumor distribution favor NF2-related schwannomatosis rather than metastatic disease.

Clinical Significance of Brainstem Compression

The reported dimensions of both tumors are clinically important, but the degree of brainstem compression deserves particular attention.

The cerebellopontine angle is a confined anatomical compartment containing several critical neurological structures.

As vestibular schwannomas enlarge, they may displace or compress:

  • The pons and medulla.

  • The cerebellar hemisphere.

  • Cranial nerve V.

  • Cranial nerve VII.

  • Cranial nerve VIII.

Progressive compression can result in worsening balance, facial sensory disturbance, facial weakness, and additional neurological deficits.

In patients with large tumors, the potential development of obstructive hydrocephalus must also be assessed.

A radiology report should therefore describe more than tumor size. It should explicitly address brainstem deformation, fourth ventricular displacement, ventricular enlargement, and associated neurological risk when present.

In this case, severe brainstem compression was documented, making the finding clinically significant even though the patient initially presented with relatively mild imbalance.

Treatment Strategy: Balancing Tumor Control and Neurological Function

Management of bilateral vestibular schwannomas in NF2-related schwannomatosis is substantially more complex than treating an isolated sporadic vestibular schwannoma.

The therapeutic objective is not simply to remove every visible tumor.

Instead, treatment must balance:

  1. Tumor growth control.

  2. Preservation of hearing.

  3. Preservation of facial nerve function.

  4. Prevention of progressive brainstem compression.

  5. Long-term neurological quality of life.

1. Microsurgical Resection

Surgical treatment may be necessary when tumors become large, produce significant brainstem compression, or cause progressive neurological deterioration.

Depending on the tumor's size, anatomical extension, and functional status, surgeons may consider complete or subtotal resection.

Subtotal resection can be an important strategy when complete tumor removal would create an unacceptable risk of neurological injury.

The decision requires detailed assessment of cranial nerve anatomy, hearing status, and the likelihood of preserving facial nerve function.

2. Stereotactic Radiation Treatment

Stereotactic radiation treatment delivers highly focused radiation to a defined target while attempting to limit exposure to surrounding structures.

It may be considered in selected patients when tumor control is required and the expected benefits outweigh the risks.

However, an important distinction must be made between sporadic vestibular schwannoma management and NF2-related schwannomatosis.

Radiation treatment in NF2-associated tumors requires particular caution because of concerns about potential long-term radiation-associated malignancy risks, especially in younger patients.

Consequently, radiation should not be regarded as an automatic or universally preferred treatment.

The decision should be individualized through multidisciplinary discussion involving neurosurgery, radiation oncology, neurotology, and specialists experienced in NF2-related schwannomatosis.

3. Hearing Rehabilitation

Hearing preservation is one of the most important considerations in bilateral vestibular schwannoma management.

In this case, the patient already had severe left-sided sensorineural hearing loss, while right-sided hearing remained normal.

The preservation of the better-hearing ear therefore represents a particularly important clinical objective.

Depending on residual auditory function and the patient's needs, hearing rehabilitation may include conventional hearing aids, cochlear implantation, or auditory brainstem implantation in selected circumstances.

Management and Long-Term Clinical Outcome in This Case

The patient underwent left-sided partial tumor resection followed by stereotactic radiation treatment directed at the left-sided tumor.

The subsequent clinical course was assessed over approximately 5 years and 10 months after the initial presentation.

At follow-up:

  • Severe left-sided hearing loss persisted.

  • The balance disturbance had resolved.

  • No new symptoms were reported.

  • Annual hearing assessments continued.

  • Annual brain MRI surveillance was maintained.

This outcome highlights an important distinction between neurological symptom improvement and auditory functional recovery.

Although the patient's balance disturbance resolved, the severe hearing impairment persisted.

Successful management of vestibular schwannomas should therefore be evaluated using multiple clinical endpoints rather than tumor appearance alone.

Tumor control, hearing preservation, facial nerve function, balance, and quality of life should all contribute to long-term assessment.

Long-Term Surveillance: Why Annual MRI and Audiology Matter

NF2-related schwannomatosis is a lifelong condition.

Even when an individual tumor is treated successfully, other schwannomas, meningiomas, or spinal tumors may develop or progress.

Long-term surveillance generally includes:

  • Serial brain MRI.

  • Spinal MRI when clinically indicated and according to the surveillance protocol.

  • Regular audiological assessment.

  • Neurological examination.

  • Ophthalmological evaluation.

  • Genetic counseling when appropriate.

The exact surveillance schedule should be individualized according to age, tumor burden, previous treatment, neurological status, and established specialist protocols.

Audiological testing is particularly important because functional hearing changes may precede obvious radiological progression.

In this patient, the continuation of annual MRI and hearing assessments provided a structured approach to monitoring both tumor behavior and neurological function.

AI in Radiology: Can Artificial Intelligence Improve Vestibular Schwannoma Surveillance?

The management of NF2-related schwannomatosis involves repeated MRI examinations over many years.

This creates a potential opportunity for medical imaging AI to support longitudinal tumor assessment.

However, AI should be considered an adjunct to expert neuroradiological interpretation, not an independent diagnostic authority.

1. Automated Tumor Detection

Deep learning-based image analysis may help identify enhancing lesions within the internal auditory canals and cerebellopontine angles.

Potential applications include:

  • Detection of small vestibular schwannomas.

  • Identification of bilateral lesions.

  • Localization of tumors along cranial nerve pathways.

  • Assistance with screening examinations.

An AI system could potentially help flag bilateral abnormalities that require further clinical evaluation.

However, detection performance must be validated specifically for small internal auditory canal lesions and patients with NF2-related disease.

2. Tumor Segmentation and Volumetric Analysis

One of the most clinically useful potential applications is automated tumor segmentation.

Serial MRI examinations can be compared to assess:

  • Tumor volume.

  • Maximum tumor dimensions.

  • Growth patterns.

  • Relationship to adjacent brainstem structures.

  • Changes following surgery or radiation treatment.

Volumetric assessment may provide additional information beyond a single linear measurement.

Nevertheless, segmentation must account for postoperative changes, treatment-related enhancement, and differences in MRI acquisition protocols.

3. Longitudinal Brainstem Compression Assessment

AI-assisted anatomical segmentation could potentially quantify changes in the relationship between the tumor and brainstem.

This may help radiologists evaluate progressive posterior fossa mass effect over time.

However, quantitative measurements should not replace direct assessment of brainstem deformation, fourth ventricular compression, and clinical symptoms.

4. AI Limitations and Diagnostic Safety

Several limitations must be considered before implementing AI-based vestibular schwannoma surveillance.

False negatives: Small lesions or subtle interval growth may be overlooked.

False positives: Normal vascular structures, postoperative enhancement, or unrelated CPA abnormalities may be incorrectly classified as tumors.

Domain shift: Differences in MRI scanners, field strength, sequences, and contrast protocols may reduce model performance.

Segmentation variability: Tumor boundaries may be difficult to define in postoperative or irradiated lesions.

Automation bias: Radiologists may place excessive confidence in automated measurements without independently reviewing the source images.

For this reason, AI-generated measurements should always be checked against the original MRI examination and prior studies.

5. Enterprise Radiology Workflow Integration

For hospitals considering AI-assisted neuroimaging workflows, practical implementation requires more than deploying an image-analysis algorithm.

A potential workflow includes:

DICOM MRI Acquisition
↓
PACS Storage
↓
AI Orchestration
↓
Tumor Detection and Segmentation
↓
Longitudinal Image Comparison
↓
PACS Visualization
↓
Radiologist Review
↓
Structured Radiology Report
↓
Clinical Decision-Making

The greatest potential benefit may come from improving consistency in serial tumor measurements and reducing the time required for longitudinal image comparison.

However, hospitals must evaluate integration costs, software maintenance, data security, radiologist adoption, and the clinical consequences of false alerts.

No specific commercial AI product or validated performance figure is established by this case.

Diagnostic Pitfalls: What Radiologists Should Not Miss

Several important diagnostic errors can occur when evaluating patients with suspected vestibular schwannomas.

Pitfall 1: Treating bilateral tumors as two unrelated sporadic lesions.

Bilateral vestibular schwannomas in a young adult should immediately raise suspicion for NF2-related schwannomatosis.

Pitfall 2: Focusing only on tumor dimensions.

Brainstem compression, fourth ventricular involvement, and cranial nerve function are essential components of the assessment.

Pitfall 3: Ignoring the contralateral internal auditory canal.

A unilateral interpretation may overlook the defining bilateral disease pattern.

Pitfall 4: Assuming radiological stability means preserved hearing.

Auditory function and tumor size do not always change in parallel.

Pitfall 5: Evaluating only the brain.

NF2-related schwannomatosis may involve the spinal canal, peripheral nerves, and ocular structures.

Pitfall 6: Overlooking the importance of genetic counseling.

Family history, de novo variants, and mosaicism have important implications for relatives and future generations.

Practical Radiology Pearls

  1. Bilateral internal auditory canal masses in a young adult should prompt consideration of NF2-related schwannomatosis.

  2. Contrast-enhanced MRI is the principal imaging modality for diagnosing vestibular schwannomas.

  3. Extension from the internal auditory canal into the cerebellopontine angle is a characteristic growth pattern.

  4. Large vestibular schwannomas can produce substantial brainstem compression even when initial neurological symptoms are relatively mild.

  5. Bilateral vestibular schwannomas fulfill a major diagnostic criterion under the updated international NF2-related schwannomatosis criteria.

  6. The NF2 gene encodes merlin, a tumor suppressor protein involved in cellular growth regulation.

  7. Hearing preservation is especially important when one ear already has severe sensorineural hearing loss.

  8. Surgical resection, radiation treatment, and observation must be selected according to tumor burden and individual neurological circumstances.

  9. Long-term MRI and audiological surveillance are essential because additional nervous system tumors may develop.

  10. AI-assisted segmentation may improve the reproducibility of longitudinal tumor measurements, but expert radiologist review remains necessary.

Frequently Asked Questions

1. What is the most characteristic MRI finding of NF2-related schwannomatosis?

The most characteristic finding is bilateral enhancing vestibular schwannomas involving both internal auditory canals, frequently with extension into the cerebellopontine angles.

2. Can bilateral vestibular schwannomas establish the diagnosis without genetic testing?

Yes. Under the 2022 international consensus diagnostic criteria, bilateral vestibular schwannomas are independently sufficient to establish the diagnosis of NF2-related schwannomatosis.

Genetic testing remains useful for molecular characterization and family counseling.

3. What gene is responsible for NF2-related schwannomatosis?

The condition is associated with pathogenic variants in the NF2 tumor suppressor gene on chromosome 22q12.2. The gene encodes the Merlin protein.

4. What other tumors are associated with NF2-related schwannomatosis?

Associated tumors include meningiomas, spinal ependymomas, peripheral nerve schwannomas, and other schwannomas involving cranial and spinal nerves.

5. Why is brainstem compression important in vestibular schwannomas?

Progressive tumor enlargement can compress the pons, medulla, and adjacent cerebellar structures, potentially resulting in neurological deterioration and obstructive hydrocephalus.

6. Is stereotactic radiation always appropriate for NF2-associated vestibular schwannomas?

No. Radiation treatment requires individualized risk-benefit assessment because of potential long-term radiation-associated malignancy concerns in NF2-related disease.

7. Why should hearing be assessed independently of MRI findings?

Tumor size and auditory function do not necessarily progress at the same rate. Serial audiological testing can identify functional deterioration that may not be adequately reflected by tumor measurements alone.

8. Can artificial intelligence help monitor vestibular schwannomas?

Potentially. AI may assist with lesion detection, segmentation, volumetric measurements, and longitudinal comparisons. However, clinical validation and expert radiologist oversight are essential.

Key Takeaways

Bilateral vestibular schwannomas are among the most recognizable imaging manifestations of NF2-related schwannomatosis.

In this 34-year-old man, contrast-enhanced MRI demonstrated bilateral internal auditory canal and cerebellopontine angle tumors measuring approximately 3 cm, with significant brainstem compression.

The case demonstrates why radiologists must look beyond individual tumor identification and recognize the underlying hereditary tumor-predisposition syndrome.

The most important clinical considerations are early recognition, assessment of brainstem compression, preservation of residual hearing, individualized treatment planning, and lifelong multidisciplinary surveillance.

As radiology AI continues to evolve, automated tumor segmentation and longitudinal MRI analysis may improve the consistency of surveillance. Nevertheless, the final diagnostic interpretation and treatment decisions must remain grounded in clinical context and specialist judgment.

INTERNAL LINK ARCHITECTURE

Parent Pillar

- Brain MRI and Neuroradiology — [INTERNAL LINK PLACEHOLDER]

Related Clinical Articles

  1. Cerebellopontine Angle Tumors: MRI Differential Diagnosis

  2. Meningioma Versus Vestibular Schwannoma on MRI

  3. MRI Diagnosis of Brainstem Compression

  4. Multiple Intracranial Tumors in Genetic Syndromes

AI and Technology Articles

  1. AI-Based Brain Tumor Segmentation

  2. Deep Learning for Automated MRI Tumor Detection

  3. AI-Powered Longitudinal Neuroimaging Analysis


References

[1] S. R. Plotkin, L. Messiaen, E. Legius, P. Pancza, S. M. Huson, P. Wolkenstein, D. G. Evans, et al., “Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation,” Genetics in Medicine, vol. 24, no. 9, pp. 1967–1977, Sep. 2022. doi: 10.1016/j.gim.2022.05.007.

[2] R. Goldbrunner, M. Weller, J. Regis, M. Lund-Johansen, P. Stavrinou, D. Reuss, et al., “EANO guideline on the diagnosis and treatment of vestibular schwannoma,” Neuro-Oncology, vol. 22, no. 1, pp. 31–45, Jan. 2020. doi: 10.1093/neuonc/noz153.

[3] M. Peyre, D. Bernardeschi, O. Sterkers, and M. Kalamarides, “Natural history of vestibular schwannomas and hearing loss in NF2 patients,” Neurochirurgie, vol. 64, no. 5, pp. 342–347, Nov. 2018. doi: 10.1016/j.neuchi.2015.03.012.

[4] S. R. Plotkin, V. L. Merker, A. Muzikansky, F. G. Barker II, and W. Slattery III, “Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients,” Otology & Neurotology, vol. 35, no. 1, pp. e50–e56, Jan. 2014. doi: 10.1097/MAO.0000000000000239.

[5] L. K. Chung, T. P. Nguyen, J. P. Sheppard, C. Lagman, S. Tenn, P. Lee, et al., “A systematic review of radiosurgery versus surgery for neurofibromatosis type 2 vestibular schwannomas,” World Neurosurgery, vol. 109, pp. 47–58, Jan. 2018. doi: 10.1016/j.wneu.2017.08.159.

[6] B. S. Kim, H. J. Seol, J.-I. Lee, H. J. Shin, K. Park, D.-S. Kong, D.-H. Nam, and Y.-S. Cho, “Clinical outcome of neurofibromatosis type 2-related vestibular schwannoma: Treatment strategies and challenges,” Neurosurgical Review, vol. 39, no. 4, pp. 643–653, Oct. 2016. doi: 10.1007/s10143-016-0728-5.

[7] C. Forde, A. T. King, S. A. Rutherford, C. Hammerbeck-Ward, S. K. Lloyd, S. R. Freeman, et al., “Disease course of neurofibromatosis type 2: A 30-year follow-up study of 353 patients seen at a single institution,” Neuro-Oncology, vol. 23, no. 7, pp. 1113–1124, Jul. 2021. doi: 10.1093/neuonc/noaa284.

[8] J. Kim, Y. Byeon, S. W. Song, Y. H. Cho, C.-K. Hong, S. H. Hong, J. H. Kim, D. H. Lee, J. E. Park, H. S. Kim, and Y.-H. Kim, “Vestibular schwannoma associated with neurofibromatosis type 2: Clinical course following stereotactic radiosurgery,” Frontiers in Oncology, vol. 12, Art. no. 996186, Sep. 2022. doi: 10.3389/fonc.2022.996186.

[9] T. Wakabayashi, R. Tamura, K. Karatsu, M. Hosoya, T. Nishiyama, Y. Inoue, et al., “Natural history of hearing and tumor growth in vestibular schwannoma in neurofibromatosis type 2-related schwannomatosis,” European Archives of Oto-Rhino-Laryngology, vol. 281, no. 8, pp. 4175–4182, Aug. 2024. doi: 10.1007/s00405-024-08601-4.

[10] S. R. Plotkin, A. O. Stemmer-Rachamimov, F. G. Barker II, C. Halpin, T. P. Padera, A. Tyrrell, A. G. Sorensen, R. K. Jain, and E. di Tomaso, “Hearing improvement after bevacizumab in patients with neurofibromatosis type 2,” The New England Journal of Medicine, vol. 361, no. 4, pp. 358–367, Jul. 2009. doi: 10.1056/NEJMoa0902579.

Medical Disclaimer

This article is intended for medical education and professional discussion. It does not replace individualized clinical evaluation, radiological interpretation, genetic counseling, or treatment recommendations from qualified healthcare professionals.

Comments

Popular posts from this blog

Understanding Tubal Ligation Clips: Imaging, Risks, Migration, and Management

Teres Minor Atrophy: Causes, Imaging, and Clinical Implications

The Lethal Lens: Mastering the Diagnosis and Management of Epidural Hemorrhage (EDH)